Clinical Trials Directory

Trials / Completed

CompletedNCT02535819

Endothelial Cell Loss After Phacoemulsification Intra and Supracapsular

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
294 (actual)
Sponsor
Centre Hospitalier Régional Metz-Thionville · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Cataract is the clouding of the lens of the eye, which initially prevents clear vision and eventually progresses to blindness if left untreated. Cataract remains the leading cause of blindness and an important cause of visual impairment across the globe. Cataract surgery by ultrasonic phacoemulsification is the most common surgery practiced in France (600 000/year) Two sub-categories of phacoemulsification coexist : Endocapsulars techniques represented by Divide-and-Conquer and Phaco-Chop ; and Supracapsular techniques mainly represented by Subluxation (similar to Tilt-and-Tumble) The corneal endothelium plays an important role in maintaining the dehydrated state and the transparency of the cornea. Some degree of endothelial cell loss invariably occurs in all types of cataract surgery but the amount of endothelial cell loss may varies with the type of surgical technique The aim of the study is to evaluate the density of the central corneal endothelial cells before and after cataract surgery comparing two phacoemulsification techniques (Divide-and-Conquer vs Subluxation)

Conditions

Interventions

TypeNameDescription
PROCEDURESubluxationOne pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete
PROCEDUREDivide and ConquerCataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration

Timeline

Start date
2015-06-01
Primary completion
2017-09-01
Completion
2018-05-01
First posted
2015-08-31
Last updated
2019-04-16

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02535819. Inclusion in this directory is not an endorsement.